AU2004210208B2 - Diagnostic imaging agents with MMP inhibitory activity - Google Patents

Diagnostic imaging agents with MMP inhibitory activity Download PDF

Info

Publication number
AU2004210208B2
AU2004210208B2 AU2004210208A AU2004210208A AU2004210208B2 AU 2004210208 B2 AU2004210208 B2 AU 2004210208B2 AU 2004210208 A AU2004210208 A AU 2004210208A AU 2004210208 A AU2004210208 A AU 2004210208A AU 2004210208 B2 AU2004210208 B2 AU 2004210208B2
Authority
AU
Australia
Prior art keywords
diagnostic imaging
compound
imaging agent
emitting
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004210208A
Other languages
English (en)
Other versions
AU2004210208A1 (en
Inventor
Joseph Arukwe
Hans-Jorg Breyholz
Alan Cuthbertson
Julie Davis
Kirsty Heywood
Klaus Kopka
Bodu Levkau
Marivi Mendizabal
Sally-Ann Ricketts
Michael Schafers
Anthony Storey
Stefan Wagner
Ian Wilson
Duncan Wynn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare Ltd
Original Assignee
GE Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0302891A external-priority patent/GB0302891D0/en
Priority claimed from GB0307524A external-priority patent/GB0307524D0/en
Application filed by GE Healthcare Ltd filed Critical GE Healthcare Ltd
Publication of AU2004210208A1 publication Critical patent/AU2004210208A1/en
Application granted granted Critical
Publication of AU2004210208B2 publication Critical patent/AU2004210208B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nuclear Medicine (AREA)
AU2004210208A 2003-02-10 2004-02-10 Diagnostic imaging agents with MMP inhibitory activity Ceased AU2004210208B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0302891.7 2003-02-10
GB0302891A GB0302891D0 (en) 2003-02-10 2003-02-10 Diagnostic imaging agents for cardiovascular disease
GB0307524.9 2003-04-01
GB0307524A GB0307524D0 (en) 2003-04-01 2003-04-01 Diagnostic imaging agents with MMP inhibitory activity
PCT/GB2004/000524 WO2004069365A1 (en) 2003-02-10 2004-02-10 Diagnostic imaging agents with mmp inhibitory activity

Publications (2)

Publication Number Publication Date
AU2004210208A1 AU2004210208A1 (en) 2004-08-19
AU2004210208B2 true AU2004210208B2 (en) 2007-06-07

Family

ID=32852413

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004210208A Ceased AU2004210208B2 (en) 2003-02-10 2004-02-10 Diagnostic imaging agents with MMP inhibitory activity

Country Status (8)

Country Link
US (1) US8231858B2 (enExample)
EP (1) EP1592458A1 (enExample)
JP (1) JP2006519216A (enExample)
AU (1) AU2004210208B2 (enExample)
CA (1) CA2514885A1 (enExample)
NO (1) NO20053776L (enExample)
RU (1) RU2005123801A (enExample)
WO (1) WO2004069365A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0326546D0 (en) * 2003-11-14 2003-12-17 Amersham Plc Inhibitor imaging agents
GB0421308D0 (en) * 2004-09-24 2004-10-27 Amersham Plc Enzyme inhibitor imaging agents
US8986650B2 (en) 2005-10-07 2015-03-24 Guerbet Complex folate-NOTA-Ga68
CA2625196C (fr) 2005-10-07 2016-04-05 Guerbet Composes comprenant une partie de reconnaissance d'une cible biologique, couplee a une partie de signal capable de complexer le gallium
ES2641727T3 (es) * 2006-10-06 2017-11-13 Mallinckrodt Nuclear Medicine Llc Sistema de elución de radioisótopos de autoalineación
EP2149568A1 (en) 2008-07-22 2010-02-03 Bracco Imaging S.p.A Aryl-sulphonamidic dimers as metalloproteases inhibitors
EP2147684A1 (en) * 2008-07-22 2010-01-27 Bracco Imaging S.p.A Diagnostic Agents Selective Against Metalloproteases
US9153350B2 (en) 2011-01-19 2015-10-06 Mallinckrodt Llc Protective shroud for nuclear pharmacy generators
US8809804B2 (en) * 2011-01-19 2014-08-19 Mallinckrodt Llc Holder and tool for radioisotope elution system
US8866104B2 (en) 2011-01-19 2014-10-21 Mallinckrodt Llc Radioisotope elution system
WO2013010573A1 (en) * 2011-07-18 2013-01-24 Universitaet Muenster Compounds with matrix-metalloproteinase inhibitory activity
US9023318B2 (en) * 2011-06-08 2015-05-05 Siemens Medical Solutions Usa, Inc. Compounds with matrix-metalloproteinase inhibitory activity and imaging agents thereof
EP2775906B1 (en) * 2011-11-11 2019-07-03 Yale University Evaluation of presence of and vulnerability to atrial fibrillation and other indications using matrix metalloproteinase-based imaging
EP2644601A1 (en) * 2012-03-28 2013-10-02 Westfälische Wilhelms-Universität Münster Compounds with matrix-metalloproteinase inhibitory activity and imaging agents thereof
GB202012671D0 (en) * 2020-08-13 2020-09-30 Nrf Ithemba Labs Theranostic Compounds

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996000214A1 (en) * 1994-06-24 1996-01-04 Ciba-Geigy Ag Arylsulfonamido-substituted hydroxamic acids as matrix metalloproteinase inhibitors
WO2001060416A2 (en) * 2000-02-15 2001-08-23 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors as targeting components in diagnostic agents
WO2001060820A2 (en) * 2000-02-15 2001-08-23 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors and uses thereof
WO2001092244A1 (en) * 2000-05-30 2001-12-06 Wayne State University Inhibitors of matrix metalloproteinases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4427646A (en) * 1981-04-02 1984-01-24 Research Corporation Use of radiolabeled peptide derived from crosslinked fibrin to locate thrombi in vivo
TW453995B (en) * 1995-12-15 2001-09-11 Novartis Ag Certain alpha-substituted arylsulfonamido acetohydroxamic acids
AU7294098A (en) * 1997-05-09 1998-11-27 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996000214A1 (en) * 1994-06-24 1996-01-04 Ciba-Geigy Ag Arylsulfonamido-substituted hydroxamic acids as matrix metalloproteinase inhibitors
WO2001060416A2 (en) * 2000-02-15 2001-08-23 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors as targeting components in diagnostic agents
WO2001060820A2 (en) * 2000-02-15 2001-08-23 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors and uses thereof
WO2001092244A1 (en) * 2000-05-30 2001-12-06 Wayne State University Inhibitors of matrix metalloproteinases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Zheng, Qi-Heng et al. (2002) Nuclear Med. and Biol. 29: 761-770 *

Also Published As

Publication number Publication date
AU2004210208A1 (en) 2004-08-19
US20070071670A1 (en) 2007-03-29
NO20053776L (no) 2005-09-30
JP2006519216A (ja) 2006-08-24
RU2005123801A (ru) 2006-03-27
US8231858B2 (en) 2012-07-31
WO2004069365A1 (en) 2004-08-19
WO2004069365A8 (en) 2004-09-30
EP1592458A1 (en) 2005-11-09
CA2514885A1 (en) 2004-08-19
NO20053776D0 (no) 2005-08-09

Similar Documents

Publication Publication Date Title
KR102766172B1 (ko) 영상화 및 치료를 위한 우레아-계 전립선 특이적 막 항원(psma) 저해제
AU2018308699B2 (en) Dual mode radiotracer and -therapeutics
AU2004210208B2 (en) Diagnostic imaging agents with MMP inhibitory activity
KR20200009091A (ko) 신규 psma-결합제 및 이의 용도
JP5043438B2 (ja) 阻害剤造影剤
LT4391B (lt) Trinariai radiofarmaciniai kompleksai
Van Staveren et al. S‐Functionalized Cysteine: Powerful Ligands for the Labelling of Bioactive Molecules with Triaquatricarbonyltechnetium‐99m (1+)([99mTc (OH2) 3 (CO) 3]+)
JP7771080B2 (ja) 医薬配合物
JP3935218B2 (ja) 放射性遷移金属窒化物へテロ錯体
KR20250073273A (ko) 고순도 구리 방사성 의약 조성물 및 이의 진단 및 치료 용도
US20080279769A1 (en) Enzyme Inhibitor Imaging Agents
JP2024507343A (ja) デュアルモード放射性トレーサーおよびその療法
JP4723378B2 (ja) 石灰化組織親和性化合物
CA2501136A1 (en) Improved imaging agents comprising barbituric acid derivatives
EP4337270A1 (en) Radiopharmaceutical somatostatin receptor ligands and precursors thereof
EP3494998A1 (en) Glycosylated psma inhibitors for imaging and endoradiotherapy
US12486294B2 (en) Radioisotope labeled compound for imaging or treatment of prostate cancer
Jowanaridhi Development of Zirconium-89 Chelators for Use in Positron Emission Tomography Imaging
HK1255215B (en) Urea-based prostate specific membrane antigen (psma) inhibitors for imaging and therapy

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired